What is new in kidney cancer?
Renal cell carcinoma is a hot topic in urologic oncology, thanks to a better understanding of the disease mechanisms, which has resulted in the developments and approval of targeted therapies. Six agents are now approved in the treatment of metastatic renal cell carcinoma. Some new information was presented at the recent Joint 15th European Cancer Organisation (ECCO) - 34th European Society of Medical Oncology (ESMO) Multidisciplinary Congress in Berlin. This article highlights the most important presentations at this meeting.
Kirkali
Ziya
Z
Dokuz Eylul University, School of Medicine, Department of Urology, Izmir, Turkey. ziya.kirkali@gmail.com
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D017277:Drug Approval; D016503:Drug Delivery Systems; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D009362:Neoplasm Metastasis; D011379:Prognosis
D000970:Antineoplastic Agents